|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 601 13th Street, NW |
Address2 | 11th Floor North |
| City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 3867-12
|
||||||||
|
6. House ID# 315600000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Jesse Kerns |
Date | 10/21/2024 4:50:53 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to drug pricing reform
Changes to Public law 117-1769 Inflation Reduction Act
Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act
S. 113 Prescription Pricing for the People Act of 2023
S.127 Pharmacy Benefit Manager Transparency Act
HR 830/ S 1375 HELP Copays Act
HR 485 Protecting Health Care for All Patients Act
HR 5378 Lower Costs, More Transparency Act
R 2534 PROTECT 340B Act of 2023
HR 3561 the PATIENT Act
S. 1542 DRUG Act
S. 1967 PBM Act
HR 3503 The NIH Clinical Trials Diversity Act
Issues related to cardiovascular disease awareness and treatment
Issues related to Federal Trade Commission
FDA issues
Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters
Biosimilars reimbursement issues, no specific bill
Supply Chain Issues, no specific bill
Issues related to 340B
Issues related to pharmacy benefit managers
Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program
HR 4818/ S. 2407 Treat and Reduce Obesity Act
S. 2305 Biosimilar Red Tape Elimination Act
S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act
Issues related to PAHPA reauthorization
Modernizing and Ensuring PBM Accountability Act (Finance Committee)
S. 652/ HR2630 SAFE Step Act
S 2474/ HR 5376 Share the Savings with Seniors Act
S 2456 Protecting Seniors from High Drug Costs Act
HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program
HR 3281 Protecting Patients Against PBM Abuses Act
HR 4822 Health Care Price Transparency Act of 2023
S 1339 Pharmacy Benefit Manager Reform Act
HR 2679 Pharmacy Benefits Manager Accountability Act
HR 4507 Transparency in Coverage Act of 2023
HR 1352 Increasing Access to Biosimilars Act of 2023
HR 2880 Protecting Patients Against PBM Abuses Act
Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions.
HR 5539 Orphan Cures Act
HR 5547 Maintaining Investments in New Innovation Act
S 3558 BIOSECURE Act
HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act)
S Res 566 Cholesterol Education Month 2024
HR 7635 340B PATIENTS Act of 2024
H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act
H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act.
HR 5376 Share the Savings With Seniors Act
S 3430 Mental Health, Lower Cost Drugs and Extenders Package.
BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities
HR 8412 Clinical Trial Modernization Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
O'Brien |
|
|
|
Helen |
Rhee |
|
|
|
Jesse |
Kerns |
|
|
|
L. Nicole |
Currie |
|
|
|
Greg |
Portner |
|
|
|
Howard |
Moon |
|
|
|
Ruth |
Hoffman |
|
|
|
Jordan |
Layson |
|
|
|
Kim |
Love |
|
|
|
Winta |
Menghis |
|
|
|
Matt |
McMurray |
|
|
|
Chad |
Pettit |
|
|
|
Chase |
Thomas |
|
Intern, Rep. Richard Nugent, October 2011-March 2012 |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to drug pricing reform
Changes to Public law 117-1769 Inflation Reduction Act
Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act
S. 113 Prescription Pricing for the People Act of 2023
S.127 Pharmacy Benefit Manager Transparency Act
HR 485 Protecting Health Care for All Patients Act
HR 5378 Lower Costs, More Transparency Act
HR 2534 PROTECT 340B act of 2023
HR 3561 the PATIENT act
Issues related to cardiovascular disease awareness and treatment
Issues related to ESRD
Issues related to asthma and self-administered drug list
Issues related to reimbursement for biologics/biosimilars
Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program
HR 4818/ S2407 Treat and Reduce Obesity Act
S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act
Issues related to PAHPA reauthorization
Modernizing and Ensuring PBM Accountability Act (Finance Committee)
S. 1542/HR 6283 DRUG Act
S652 SAFE Step Act
HR 3281 Protecting Patients Against PBM Abuses Act
HR 4822 Health Care Price Transparency Act of 2023
S 1339 Pharmacy Benefit Manager Reform Act
HR 2679 Pharmacy Benefits Manager Accountability Act
HR 4507 Transparency in Coverage Act of 2023
S 2474/HR 5376 Share the Savings with Seniors Act
S 2456 Protecting Seniors from High Drug Costs Act
HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program
HR 1352 Increasing Access to Biosimilars Act of 2023
HR 2880 Protecting Patients Against PBM Abuses Act
HR 5547 Maintaining Investments in New Innovation Act
HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act)
HR 7635 340B PATIENTS Act of 2024
H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act
H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act.
HR 5376 Share the Savings With Seniors Act.
S 3430 Mental Health, Lower Cost Drugs and Extenders Package
HR 5539 Orphan Cures Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
L. Nicole |
Currie |
|
|
|
Greg |
Portner |
|
|
|
Helen |
Rhee |
|
|
|
Jesse |
Kerns |
|
|
|
William |
O'Brien |
|
|
|
Howard |
Moon |
|
|
|
Ruth |
Hoffman |
|
|
|
Jordan |
Layson |
|
|
|
Kim |
Love |
|
|
|
Winta |
Menghis |
|
|
|
Matt |
McMurray |
|
|
|
Chad |
Pettit |
|
|
|
Chase |
Thomas |
|
Intern, Rep. Richard Nugent, October 2011-March 2012 |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act
Issues related to Puerto Rico
Issues related to OECD negotiations on the taxation of global income
HR 3938 Build it in America Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
L. Nicole |
Currie |
|
|
|
Helen |
Rhee |
|
|
|
Jordan |
Layson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 79/HR 1717 Interagency Patent Coordination and Improvement Act of 2023
S. 113 Prescription Pricing for the People Act of 2023
. S. 1250 Drug-price Transparency for Consumers Act
S.127 Pharmacy Benefit Transparency Act
S. 150 Affordable Prescriptions for Patients Act of 2023
S. 148 Stop STALLING Act
S. 142 Preserve Access to Affordable Generics and Biosimilars
Federal Trade Commission related issues, no specific bill
Issues related to the Patent Act, no specific bill
Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill
Issues related to patent thickets/product hopping
Issues related to obviousness/ double patenting
S.2140 Patent Eligibility Restoration Act of 2023
S.2220/HR 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act
S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents
H.R. 3858/S.1834: A bill to prohibit the President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress.
H.R. 3535 Advancing Americas Interests Act
H.R. 5475 Prohibiting Adversarial Patents Act of 2023
S.3385/HR 8333-- BIOSECURE Act
BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities
Issues related to FDA/PTO coordination
S.2780 Medication Affordability and Patent Integrity Act
Issues related to skinny labeling
S. 3583/HR 6986 To Address Patent Thickets
S. 1956 Invent It Here, Make It Here Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Rhee |
|
|
|
Greg |
Portner |
|
|
|
L. Nicole |
Currie |
|
|
|
William |
O'Brien |
|
|
|
Howard |
Moon |
|
|
|
Jesse |
Kerns |
|
|
|
Jordan |
Layson |
|
|
|
Kim |
Love |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |